Cargando…

Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?

Detalles Bibliográficos
Autores principales:	Tang, Jordan, Ghosh, Arun
Formato:	Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2011
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047132/ https://www.ncbi.nlm.nih.gov/pubmed/21248377

Ejemplares similares

Enhancing α-secretase Processing for Alzheimer’s Disease—A View on SFRP1
por: Tang, Bor Luen
Publicado: (2020)

Understanding the lingering consequences of what we treat and what we do
por: Angus, Derek C
Publicado: (2004)

Beneficial Effect of Antibodies against β- Secretase Cleavage Site of App on Alzheimer’s-Like Pathology in Triple-Transgenic Mice
por: Rabinovich-Nikitin, Inna, et al.
Publicado: (2012)

Ferulic Acid Is a Nutraceutical β-Secretase Modulator That Improves Behavioral Impairment and Alzheimer-like Pathology in Transgenic Mice
por: Mori, Takashi, et al.
Publicado: (2013)

Phenotypic analysis of images of zebrafish treated with Alzheimer's γ-secretase inhibitors
por: Arslanova, Dilyara, et al.
Publicado: (2010)

Commentary: Thoracoscopic-Assisted Rib Plating: Where We Are and What We Have Learned
por: Kim, Seon Hee, et al.
Publicado: (2023)

Gene expression in human sepsis: what have we learned?
por: Russell, James A
Publicado: (2011)

Metasynthetic Madness: What Kind of Monster Have We Created?
por: Thorne, Sally
Publicado: (2016)

Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer’s Therapeutics
por: Mouchlis, Varnavas D., et al.
Publicado: (2020)

β-Secretases, Alzheimer's Disease, and Down Syndrome
por: Webb, Robin L., et al.
Publicado: (2012)

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease
por: Menting, Kelly Willemijn, et al.
Publicado: (2014)

Time-restricted feeding: what we have done and what more we can do?
por: Sun, Yuning, et al.
Publicado: (2023)

Commentary: What do we still have to learn from surgery?
por: Belluschi, Igor, et al.
Publicado: (2021)

Surrogate end points of quality of life assessment: have we really found what we are looking for?
por: Tassinari, Davide
Publicado: (2003)

Activity of Alzheimer’s γ-secretase is linked to changes of interferon-induced transmembrane proteins (IFITM) in innate immunity
por: Yao, Annie Y., et al.
Publicado: (2020)

IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

What have we learned from cancer immunotherapy in the last 3 years?
por: Ascierto, Paolo A, et al.
Publicado: (2014)

History of gestational diabetes and future cardiovascular disease: What have we learned?
por: Hsu, Cherng‐Lan, et al.
Publicado: (2018)

Coronavirus Disease 2019 and Acute Kidney Injury: What Have We Learned?
por: Husain-Syed, Faeq, et al.
Publicado: (2021)

COVID-19 and patient engagement in health research: What have we learned?
por: Denegri, Simon, et al.
Publicado: (2021)

Commentary: Patient Perspectives on Artificial Intelligence; What have We Learned and How Should We Move Forward?
por: Camaradou, Jennifer Catherine Louise, et al.
Publicado: (2023)

The Alzheimer's disease β-secretase enzyme, BACE1
por: Cole, Sarah L, et al.
Publicado: (2007)

γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease?
por: Toyn, Jeremy H., et al.
Publicado: (2013)

Design of potent and highly selective inhibitors for human β-secretase 2 (memapsin 1), a target for type 2 diabetes
por: Ghosh, Arun K., et al.
Publicado: (2016)

Acute stroke: we have the treatments and we have the evidence – we need to use them
por: Quinn, Terence J, et al.
Publicado: (2007)

Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2005)

Parliaments lead the change for women’s, children’s and adolescents’ health: what have we learnt?
por: Toure, Kadidiatou, et al.
Publicado: (2021)

Alzheimer’s Transgenic Model Is Characterized by Very Early Brain Network Alterations and β-CTF Fragment Accumulation: Reversal by β-Secretase Inhibition
por: Mondragón-Rodríguez, Siddhartha, et al.
Publicado: (2018)

Delta-secretase triggers Alzheimer’s disease pathologies in wild-type hAPP/hMAPT double transgenic mice
por: Wu, Zhourui, et al.
Publicado: (2020)

Qualitative research on community experiences in large HIV research trials: what have we learned?
por: Camlin, Carol S, et al.
Publicado: (2018)

Proximal tubular dysfunction in patients with COVID-19: what have we learnt so far?
por: Braun, Fabian, et al.
Publicado: (2020)

Estimating maternal mortality: what have we learned from 16 years of surveys in Afghanistan?
por: Alba, Sandra, et al.
Publicado: (2020)

Cannabis use in first episode psychosis: what we have tried and why it hasn’t worked
por: McDonell, Michael G., et al.
Publicado: (2019)

Violence against children in the time of COVID-19: What we have learned, what remains unknown and the opportunities that lie ahead
por: Fore, Henrietta H.
Publicado: (2021)

Targeting cytokine storm in COVID-19: what have we learned?
por: Ridker, Paul M
Publicado: (2021)

β-Secretase-1: In Silico Drug Reposition for Alzheimer’s Disease
por: Galeana-Ascencio, Roberto A., et al.
Publicado: (2023)

The Patients We Have to See
por: Irwin, Kelly E.
Publicado: (2017)

Repression of Alzheimer's beta-Secretase
por: Liao, Francesca-Fang, et al.
Publicado: (2013)

γ-Secretase in Alzheimer’s disease
por: Hur, Ji-Yeun
Publicado: (2022)

Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?
por: Ewer, Michael S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7sll8t9g882a5vu85l0msu9vuo